To solve this problem, researchers from the groups of Zack Z. Wang (Johns Hopkins) and Linzhao Cheng (Johns Hopkins) have sought to create a robust and efficient means to generate expandable MK progenitors from hiPSCs using Food and Drug Administration (FDA)-
approved pharmacological agents [3].